Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses (2010 - 2026)

Jazz Pharmaceuticals has reported Change in Accured Expenses for 17 years, with the latest figure at -$7.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 372.41% year-over-year to -$7.9 million; the trailing twelve-month figure through Mar 2026 stood at $17.2 million (down 68.34% YoY), and the FY2025 full-year result was $28.0 million, down 67.48% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$7.9 million, up from -$22.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $148.1 million in Q4 2022, with the low at -$97.0 million in Q1 2023.
• Average Change in Accured Expenses over 5 years is $14.6 million, with a median of $7.2 million recorded in 2023.
• Peak annual rise in Change in Accured Expenses reached 276.64% in 2024, while the deepest fall reached 507.87% in 2024.
• Tracing JAZZ's Change in Accured Expenses over 5 years: stood at $148.1 million in 2022, then slumped by 64.45% to $52.7 million in 2023, then slumped by 43.54% to $29.7 million in 2024, then tumbled by 177.05% to -$22.9 million in 2025, then jumped by 65.51% to -$7.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$7.9 million (Q1 2026), -$22.9 million (Q4 2025), and $126.3 million (Q3 2025), per Business Quant data.

Peer Comparison